左醋美沙朵乙酸酯盐酸盐 | 43033-72-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 左醋美沙朵乙酸酯盐酸盐
• 中文别名: LAAM盐酸盐；LAAM 盐酸盐
• 英文名称: levomethadyl acetate hydrochloride
• 英文别名: 6-dimethylamino-4,4-diphenyl-3-acetoxyheptane hydrochloride；(-)-α-acetylmethadol hydrochloride；L-α-acetylmethadol hydrochloride；Levo-alpha-acetylmethadol hydrochloride；levo-α-acetylmethadol hydrochloride；[(3S,6S)-6-(dimethylamino)-4,4-diphenylheptan-3-yl] acetate;hydrochloride
• CAS: 43033-72-3
• 化学式: C₂₃H₃₁NO₂*ClH
• 分子量: 389.966
• InChiKey: UXBPQRGCVJOTNT-COBSGTNCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.08
• 重原子数：
  27
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 储存条件：
  | 库房应保持通风、低温和干燥环境 |

反应信息

• 作为产物：
  描述：

  (S)-methadone hydrochloride 在 sodium tetrahydroborate 、 cerium(III) chloride 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 12.0h， 生成 左醋美沙朵乙酸酯盐酸盐
  参考文献：
  名称：

  Synthesis of optically active methadones, LAAM and bufuralol by lipase-catalysed acylations

  摘要：

  (R)- and (S)-Methadones and levo-alpha-acetylmethadol (LAAM) have been synthesised starting from lipase-catalysed acylation of dimethylaminopropan-2-ol. An approach to the synthesis of (R)-bufuralol is also presented. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(03)00019-3

文献信息

• [EN] PEPTIDE-BASED MULTIPLE-DRUG DELIVERY VEHICLE<br/>[FR] VÉHICULE D'ADMINISTRATION DE MÉDICAMENTS MULTIPLES À BASE DE PEPTIDES
  申请人：ARIEL-UNIVERSITY RES AND DEV COMPANY LTD

  公开号：WO2017068577A1

  公开（公告）日：2017-04-27

  A molecular structure comprising a targeting moiety, a multi-functional peptide platform and a plurality of controllably released bioactive agents attached thereto is provided herein.

  本文提供了一种包括靶向基团、多功能肽平台和附着在其上的多种可控释放的生物活性剂的分子结构。
• [EN] BUPRENORPHINE ANALOGS<br/>[FR] ANALOGUES DE BUPRÉNORPHINE
  申请人：PURDUE PHARMA LP

  公开号：WO2012038813A1

  公开（公告）日：2012-03-29

  The present invention is directed to Buprenorphine Analog compounds of the Formula (I), Formula (IA) or Formula (IB) shown below, wherein R1, R2, R8, R 3a, R 3b, G, X, Z and Y are as defined herein. Compounds of the Invention are useful for treating pain, constipation, and other conditions modulated by activity of opioid and ORL-1 receptors.

  本发明涉及如下所示的公式(I)、公式(IA)或公式(IB)的丁丙诺啡类似物化合物，其中R1、R2、R8、R 3a、R 3b、G、X、Z和Y的定义如本文所述。本发明的化合物可用于治疗疼痛、便秘以及通过阿片类和ORL-1受体的活性调节的其他状况。
• Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments
  申请人：NEUROVANCE, Inc.

  公开号：US20140303207A1

  公开（公告）日：2014-10-09

  The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.

  本发明提供了新型的1-杂芳基-3-氮杂双环[3.1.0]己烷化合物，以及用于制备这些化合物的相关过程和中间体，还包括使用这些化合物的组合物和方法，用于治疗和/或预防中枢神经系统（CNS）疾病，包括但不限于抑郁症和焦虑症。
• [EN] THERANOSTIC CONJUGATES<br/>[FR] CONJUGUÉS THÉRANOSTIQUES
  申请人：ARIEL SCIENT INNOVATIONS LTD

  公开号：WO2021009759A1

  公开（公告）日：2021-01-21

  Provided herein is a drug delivery (DD) system for ratiometric luminescence determination of drug release degree in drug delivery monitoring, which includes a drug, a switchable reporter and non-switchable reporter providing two distinguishable signals for detection; or a single switchable reporter providing two distinguishable signals for detection, and a cleavable linker connecting a drug to a switchable reporter, as well as a method for ratiometric luminescence determination of drug release in a target in vivo or in vitro), which is effected by administering the DD system provided herein that is capable of releasing a drug from the DD system, measuring two luminescent signals provided by the switchable reporter and the non-switchable reporter, or the single switchable reporter, determining the ratio between these two luminescence signals, and determining the drug release degree through the ratio between the two luminescence signals.

  本文提供了一种药物递送（DD）系统，用于药物递送监测中药物释放程度的比例荧光测定，该系统包括一种药物、一种可切换的报告物和一种不可切换的报告物，用于提供两种可区分的信号以进行检测；或者一种单一可切换的报告物，用于提供两种可区分的信号以进行检测，以及一种可切割的连接剂，连接药物和可切换的报告物，以及一种比例荧光测定方法，用于在目标（体内或体外）中测定药物释放，通过给予本文提供的能够从DD系统中释放药物的DD系统，测量可切换的报告物和不可切换的报告物提供的两个发光信号，或者单一可切换的报告物，确定这两个发光信号之间的比例，并通过这两个发光信号之间的比例确定药物释放程度。
• [EN] SUBSTITUTED PIPERIDIN-4-AMINO-TYPE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TYPE PIPÉRIDINE-4-AMINO SUBSTITUÉE ET LEURS UTILISATIONS
  申请人：PURDUE PHARMA LP

  公开号：WO2014102590A1

  公开（公告）日：2014-07-03

  The disclosure relates to Substituted Piperidin-4-amino-Type Compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1, R2, R3, Q1, Q2, E1, E2, A, B, D, W, Z, a, b, n, and x are as defined herein, compositions comprising an effective amount of a Substituted Piperidin-4-amino-Type Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted Piperidin-4-amino-Type Compound.

  本发明涉及式(I)的取代哌啶-4-氨基型化合物及其药物可接受的盐和溶剂化物，其中R1，R2，R3，Q1，Q2，E1，E2，A，B，D，W，Z，a，b，n和x按本文定义，包含有效量的取代哌啶-4-氨基型化合物的组合物，以及治疗或预防诸如疼痛等症状的方法，包括向需要的动物施用有效量的取代哌啶-4-氨基型化合物。